Full-Time

Senior Strategy Manager

Global Services AI and Automation

Posted on 8/20/2026

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Bachelor's

Category
Business & Strategy (1)
Required Skills
LLM
Agile
Six Sigma
Data Visualization
Machine Learning
CRM
Cybersecurity
Data Governance
Data Analysis

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • A bachelor's degree in Information Systems, Computer Science, Engineering, Business, Data Science, or a related field, or 10+ years of experience in business systems, automation, digital transformation, process improvement, or technology leadership.
  • At least 5 years of leadership experience managing technical, business systems, or transformation teams.
  • Experience implementing artificial intelligence, automation, analytics, or digital transformation initiatives at enterprise scale.
  • Strong understanding of service operations, customer support, field service, or customer experience processes.
  • Experience with enterprise platforms such as customer relationship management, workflow automation, and analytics solutions.
  • Demonstrated ability to build business cases and deliver measurable business outcomes.
  • Strong stakeholder management and executive communication skills.
  • Experience in the medical device, healthcare, life sciences, or another regulated industry, with knowledge of GxP, computer system validation, artificial intelligence governance, and risk management frameworks.
  • Experience with generative artificial intelligence, machine learning, intelligent automation, robotic process automation, and predictive analytics.
  • Familiarity with artificial intelligence governance, responsible artificial intelligence principles, and data privacy regulations.
Responsibilities
  • Develop and execute a multi-year artificial intelligence and automation roadmap aligned with Global Services and enterprise objectives.
  • Identify opportunities to leverage artificial intelligence, machine learning, generative artificial intelligence, robotic process automation, workflow automation, and predictive analytics.
  • Establish an innovation framework balancing experimentation, governance, risk management, and business value realization.
  • Drive adoption of emerging technologies to improve customer and employee experiences.
  • Partner with business leaders to assess operational challenges and identify opportunities for automation and optimization.
  • Lead process improvement initiatives focused on reducing manual effort, increasing scalability, and improving service delivery performance.
  • Facilitate automation opportunity assessments and prioritization workshops across Global Services functions.
  • Establish metrics and reporting to measure automation effectiveness and return on investment.
  • Lead the design, development, implementation, and support of artificial-intelligence-enabled solutions and automation platforms.
  • Oversee delivery of solutions supporting customer relationship management, service operations, customer support, knowledge management, telephony, field service, and customer-facing technologies.
  • Collaborate with enterprise architecture and information technology teams to ensure solutions are scalable, secure, and integrated.
  • Establish standards, methodologies, and best practices for artificial intelligence and automation development for Global Services that align with corporate requirements.
  • Create governance processes for artificial intelligence and automation initiatives, including intake, prioritization, approvals, and monitoring for Global Services.
  • Ensure solutions comply with applicable regulations, quality system requirements, and data privacy standards.
  • Partner with Quality, Regulatory, Legal, Privacy, and Cybersecurity teams to assess risks associated with artificial intelligence solutions as required.
  • Support validation activities for systems operating within regulated environments and ensure appropriate documentation is maintained.
  • Promote data-driven decision-making through advanced analytics, dashboards, and operational insights.
  • Partner with business, analytics, and information technology stakeholders to improve data quality, accessibility, and governance.
  • Leverage artificial intelligence and analytics to identify trends, predict service demand, improve customer support outcomes, and optimize resource utilization.
  • Evaluate emerging artificial intelligence and automation technologies, vendors, and strategic partnerships.
  • Manage vendor relationships and contracts related to artificial intelligence, automation, and analytics solutions.
  • Lead proof-of-concept initiatives and business case development for new technologies.
  • Build and lead a high-performing team of artificial intelligence, Automation, Business Systems, and Process Excellence professionals.
  • Foster a culture of innovation, experimentation, accountability, and continuous improvement.
  • Coach team members on emerging technologies, business process optimization, and digital transformation methodologies.
  • Develop organizational capabilities that support long-term artificial intelligence adoption and operational excellence.
Desired Qualifications
  • Lean Six Sigma, Process Excellence, Agile, or Project Management certifications.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates on July 16.
  • Penang lease adds 316,000 square feet and 1,200 jobs, supporting Asia-Pacific growth.
  • Management kept 2026 da Vinci growth at 13.5%-15.5% and raised gross-margin guidance.

What critics are saying

  • FDA recall tracker listed multiple 2026 da Vinci Class II recalls, signaling quality-control strain.
  • Medtronic Hugo gained U.S. urology clearance in December 2025, tightening robotic-surgery competition.
  • 2027 extended instrument-use changes risk recurring revenue erosion if hospitals delay upgrades.

What makes Intuitive Surgical unique

  • Da Vinci installed base neared 13,000 systems worldwide, locking in switching costs.
  • Da Vinci 5 launched broadly in the U.S. in 2025, boosting utilization.
  • Ion procedures grew 36% in Q2 2026, extending Intuitive beyond soft-tissue robotics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.

Yahoo Finance
Aug 8th, 2026
Medtronic and Intuitive Surgical lag market amid sector weakness

Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.